Study of Preoperative Lugols Solution to Reduce Surgical Risks in Hyperthyroidism Treatment Before Thyroidectomy for Graves Disease and Toxic Nodular Goiter

What this Trial Is About

This research evaluates whether preoperative treatment with Lugols solution before thyroidectomy can reduce surgical complications such as hypoparathyroidism and laryngeal nerve palsy in patients with hyperthyroidism caused by Graves disease or toxic nodular goiter. The study addresses a gap in evidence, particularly regarding the use of iodine in toxic nodular goiter cases, aiming to improve surgical outcomes for these conditions. Participants are randomly assigned to receive either Lugols solution oral drops three times daily for 10 days before surgery in addition to standard preoperative care, or standard preoperative treatment alone. A pilot study on patients with toxic nodular goiter will measure thyroid hormone levels and heart rate during the treatment period. The intervention involves an iodine potassium iodide 5% oral solution administered as the investigational drug. During the study, participants will be monitored for temporary and permanent complications such as hypoparathyroidism and laryngeal nerve palsy at 1 and 6 months postoperatively. Assessments include thyroid hormone measurements, heart rate, and patient-reported outcomes using ThyPRO39 questionnaires. The total follow-up period extends to at least 6 months after surgery to evaluate the primary and secondary surgical outcomes and ensure safety.

Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter